证券代码：301293 证券简称：三博脑科 公告编号：2025-012 三博脑科医院管理集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 1、三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开第三届董事会第十二次会议和第三届监事会第十次会议，审议通过 了《关于 2024 年度利润分配预案的议案》，本议案尚需提交公司 2024 年年度股 东会审议。 2、监事会意见：本次利润分配预案符合公司实际情况，有利于保障公司持 续发展、平稳运营，充分考虑了中小投资者的利益和合理诉求，不存在损害公司 及股东特别是中小股东利益的情形，符合相关法律法规及《公司章程》的有关规 定，具备合法性、合规性、合理性，同意此利润分配预案。 3、独立董事专门会议意见：公司 2024 年度利润分配预案，是董事会综合考 虑公司的经营现状和未来发展规划，以及对投资者的合理回报制定的，我们认为 本次利润分配方案符合公司实际情况，有利于与股东共享公司发展成果和公司可 持续发展目标的实现，符合相关 ...

三博脑科（301293）公告，2024年营业收入14.29亿元，同比增长8.84%。归属于上市公司股东的净利润 1.05亿元，同比增长34.24%。基本每股收益0.51元/股，同比增长24.39%。公司拟向全体股东每10股派发 现金红利1.48元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Sanbo Neuroscience, which has a current stock price of 45.2 yuan and a rolling PE ratio of 84.92 times, significantly higher than the industry average of 46.29 times [1][2] - As of September 30, 2024, Sanbo Neuroscience has 27,403 shareholders, an increase of 2,446 from the previous period, with an average holding value of 352,800 yuan per shareholder [1] - The company specializes in clinical medical services in neurology, with a focus on complex surgeries, achieving a high volume of operations, particularly in advanced neurosurgery [1] Group 2 - In the latest financial report for Q3 2024, Sanbo Neuroscience reported a revenue of 1.059 billion yuan, representing a year-on-year increase of 9.83%, and a net profit of 105 million yuan, up 42.93% year-on-year, with a gross margin of 24.97% [1] - The company ranks 37th in terms of PE ratio within the medical services industry, which has an average PE of 46.29 times and a median of 47.83 times [2]

证券代码：301293 证券简称：三博脑科 公告编号：2025-007 三博脑科医院管理集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开第三届董事会第四次会议，审议通过了《关于回购公司股份方案的议案》， 拟使用不低于 8,000 万元（含本数）且不超过 16,000 万元（含本数）的自有资金 以集中竞价交易方式回购公司已发行的人民币普通股（A 股），并在未来适宜时 机将回购股份用于股权激励或员工持股计划。因公司实施 2023 年年度权益分派 方案，公司对本次回购价格上限进行了调整，由 90 元/股调整为 69.16 元/股。在 回购价格不超过 69.16 元/股（含本数）的条件下，按照本次回购资金总额上限测 算，回购数量约为 2,313,475 股，约占公司总股本的 1.12%；按照本次回购资金 总额下限测算，回购数量约为 1,156,737 股，约占公司总股本的 0.56%。本次回 购实施期限自董事会审议通过本次回购股份方案 ...

Group 1 - The core viewpoint of the article highlights the performance and market position of Sanbo Brain Science, noting its significant growth in revenue and net profit, alongside a high PE ratio compared to industry averages [1] - As of April 1, Sanbo Brain Science's stock closed at 49.29 yuan, with a PE ratio of 92.60 and a total market capitalization of 10.153 billion yuan [1] - The company ranks 37th in the medical services industry, which has an average PE ratio of 52.86 and a median of 49.90 [1] Group 2 - Sanbo Brain Science specializes in clinical medical services in neurology, including neurosurgery, neurointervention, and neuro-oncology treatments [1] - The company has a strong team of medical experts, which has led to a high volume of complex neurosurgeries, with 80% classified as the most difficult level [1] - For the third quarter of 2024, Sanbo Brain Science reported a revenue of 1.059 billion yuan, a year-on-year increase of 9.83%, and a net profit of 105 million yuan, reflecting a 42.93% increase [1]

Key Points - The article emphasizes the Chinese government's commitment to implementing proactive macro policies to support economic stability and growth, including potential new policies if necessary [2] - The article highlights the importance of enhancing the business environment for various enterprises through economic reforms and addressing bottlenecks in economic circulation [2] - The article discusses the upcoming significant events in the global market, including earnings reports from major companies and important economic data releases [4] Macro - Premier Li Qiang met with U.S. senators, stating that trade wars yield no winners and emphasizing the need for cooperation to address trade imbalances [6] - Vice Premier He Lifeng welcomed multinational companies to invest in China, highlighting the resilience and potential of the Chinese economy [6] - The government plans to deepen supply-side structural reforms and regulate competition to promote high-quality development [6] Domestic Stock Market - CITIC Securities identified two critical time points for the market: the first in early April when external risks are expected to materialize, and the second mid-year when U.S. economic and policy cycles may align with China's [9] - The "Leading Enterprise" action plan in Guangzhou aims to enhance the integration of industry and capital, promoting more competitive companies to go public [9] - The report notes a significant increase in new account openings at several securities firms, indicating growing market participation [10] Financial - A surge in the number of funds focusing on free cash flow indicates a market trend towards financial health metrics, driven by demand and policy direction [14] - The head of the Industrial and Commercial Bank of China emphasized the shift from a capital-centric to a technology-centric financial service model [14] Real Estate - Suggestions were made to stabilize asset prices and improve income levels to boost consumer spending, particularly in real estate and equity markets [17] Industry - XPeng Motors' chairman discussed the future of high-level autonomous driving technology, predicting significant advancements in the coming years [19] - The Henan province announced plans for extensive 5G infrastructure development, aiming for over 270,000 5G base stations in the next three years [19] Overseas - The WTO Director-General highlighted the U.S. as a major beneficiary of global trade, countering claims of trade disadvantages [21] - The UK government plans to invest £600 million to address skill shortages in the construction sector, crucial for housing development [22] International Stock Market - SpaceX aims to achieve a weekly launch frequency for its Starship within a year, enhancing its operational capabilities [23] Commodity - The China Iron and Steel Association noted that supply-demand imbalances are a key issue in the industry, advocating for the closure of new production capacity [26] - Methanol port inventories have decreased, indicating a market shift towards destocking [26] - BHP's CEO projected a significant copper supply gap in the next decade, emphasizing the need for substantial investment in mining [26] Bonds - The government plans to issue long-term special bonds to support various initiatives, with a focus on local government debt management [28] - The AI and robotics sectors are identified as key drivers of market growth, with expectations for increased investment opportunities [28]

人民财讯3月23日电，三博脑科(301293)3月23日晚间公告，持有公司股份15.93%的股东TBP 3Doctors (HK) Limited（以下简称"TBP"）计划以集中竞价方式减持本公司股份不超过113.21万股（占剔除公司回 购专用账户股份数量后总股本的0.56%）。 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-006 三博脑科医院管理集团股份有限公司 关于持股 5%以上股东减持股份的预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 持有三博脑科医院管理集团股份有限公司（以下简称"公司"）股份 32,330,025 股（占剔除公司回购专用账户股份数量后总股本的 15.93%）的持股 5%以上股东 TBP 3Doctors (HK) Limited（以下简称"TBP"）计划在本公告披露之日起十五个 交易日后的三个月内以集中竞价方式减持本公司股份不超过 1,132,075 股（占剔 除公司回购专用账户股份数量后总股本的 0.56%）。 一、股东减持公司股份计划 公司收到股东 TBP 出具的《关于股份减持计划的告知函》，现将相关情况 公告如下： 1、计划减持股东的情况 截至本公告披露日，本次拟减持的股东持有公司股份情况如下： | | 股东名称 | | 持股数量（股） | 占剔除公司回购专用账户 | | --- | --- | --- | --- | --- | | | | | | 股份数量 ...

Investment Rating - The report maintains a "Positive" investment rating for the brain-computer interface (BCI) industry [1]. Core Insights - The BCI technology has significant potential in the healthcare sector, particularly for improving the quality of life for patients with severe motor disabilities and other neurological disorders [4]. - The global BCI market is experiencing rapid growth, with a compound annual growth rate (CAGR) of 11.85% from 2018 to 2023, projected to reach $10.8 billion by 2033, with a CAGR of 16.48% from 2023 to 2033 [4][25]. - The Chinese BCI market is also expanding quickly, expected to reach 5.58 billion yuan by 2027, with a CAGR of 20.29% [4]. - The healthcare sector accounted for 46.14% of the BCI market share in 2024, with potential market sizes in serious medical applications estimated between $15 billion and $85 billion by 2030-2040 [4][32]. Summary by Sections 1. Introduction to Brain-Computer Interfaces - BCI technology interprets brain signals to control external devices, significantly benefiting patients with severe motor disabilities [11]. - The development of BCI technology has gained global attention, with various projects moving from laboratory settings to practical applications [11]. 2. Investment Landscape of Brain-Computer Interfaces - The global BCI market size grew from $1.2 billion in 2018 to $2.35 billion in 2023, with non-invasive BCI being the primary research focus [25]. - Major countries are supporting BCI technology through various initiatives, including the U.S. "Brain Research Initiative" and the EU's "Human Brain Project" [28]. 3. Key Technologies and Current Development Status - BCI systems are categorized into input and output types, with various signal acquisition methods including invasive, semi-invasive, and non-invasive techniques [20][24]. - The report highlights the challenges faced by BCI technology, including complex EEG signals and limitations in decoding accuracy [4]. 4. Company Analysis in the BCI Sector - Notable companies in the BCI field include Cheng Yi Tong, Xiang Yu Medical, and Sanbo Neuroscience, which are recognized for their advancements in BCI technology [4].

三博脑科医院管理集团股份有限公司 反舞弊与举报制度 第一章 总则 1 目的 为加强三博脑科医院管理集团股份有限公司（以下简称"公司"）的内部控制，规范公司员工 行为，降低公司经营风险，维护公司和股东合法权益，确保公司经营目标的实现和公司持续稳 定发展，根据《中华人民共和国证券法》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》《企业内部控制基本规范》《中华人民共和国公司法》《中华人民 共和国审计法》等法律、行政法规、部门规章、规范性文件的要求，结合公司实际情况，制定 本制度。 反舞弊工作的宗旨是规范公司全体员工的职业行为，严格遵守相关法律法规、行业规范、职业 道德及公司的规章制度，树立廉洁和勤勉敬业的良好风气，防止损害公司及股东的利益的行为 发生。 2 适用范围 本制度适用于三博脑科医院管理集团股份有限公司及分子公司。 3 定义 5.1 管理层负责建立健全包括预防舞弊在内的内部控制机制； 5.2 管理层负责实施控制措施以降低舞弊发生的机会，对舞弊行为采取适当且有效的补救措施， 并进行自我评估。 6 审计部 1 6.1 审计部是公司反舞弊的责任部门； 3.1 本制度所称舞弊是指公司内 ...